OBJECTIVES: Acute and chronic rejection remain unresolved problems after lung transplantation, despite heavy multidrug immunosuppression. In turn, the strong immunosuppression has been responsible for mortality and pervasive morbidity. It also has been postulated to interdict potential mechanisms of alloengraftment. METHODS: In 48 lung recipients we applied 2 therapeutic principles: (1) recipient pretreatment with antilymphoid antibody preparations (Thymoglobulin [SangStat, Fremont, Calif] or Campath [alemtuzumab; manufactured by ILEX Pharmaceuticals, LP, San Antonio, Tex; distributed by Berlex Laboratories, Richmond, Calif]) and (2) minimal posttransplant immunosuppression with tacrolimus monotherapy or near-monotherapy. Our principal analysis was of the events during the critical first 6 posttransplant months of highest immunologic and infectious disease risk. Results were compared with those of 28 historical lung recipients treated with daclizumab induction and triple immunosuppression (tacrolimus-prednisone-azathioprine). RESULTS: Recipient pretreatment with both antilymphoid preparations allowed the use of postoperative tacrolimus monotherapy with prevention or control of acute rejection. Freedom from rejection was significantly greater with Campath than with Thymoglobulin (P = .03) or daclizumab (P = .05). After lymphoid depletion with Thymoglobulin or Campath, patient and graft survival at 6 months was 90% or greater. Patient and graft survival after 9 to 24 months is 84.2% in the Thymoglobulin cohort, and after 10 to 12 months, it is 90% in the Campath cohort. There has been a subjective improvement in quality of life relative to our historical experience. CONCLUSION: Our results suggest that improvements in lung transplantation can be accomplished by altering the timing, dosage, and approach to immunosuppression in ways that might allow natural mechanisms of alloengraftment and diminish the magnitude of required maintenance immunosuppression.
OBJECTIVES: Acute and chronic rejection remain unresolved problems after lung transplantation, despite heavy multidrug immunosuppression. In turn, the strong immunosuppression has been responsible for mortality and pervasive morbidity. It also has been postulated to interdict potential mechanisms of alloengraftment. METHODS: In 48 lung recipients we applied 2 therapeutic principles: (1) recipient pretreatment with antilymphoid antibody preparations (Thymoglobulin [SangStat, Fremont, Calif] or Campath [alemtuzumab; manufactured by ILEX Pharmaceuticals, LP, San Antonio, Tex; distributed by Berlex Laboratories, Richmond, Calif]) and (2) minimal posttransplant immunosuppression with tacrolimus monotherapy or near-monotherapy. Our principal analysis was of the events during the critical first 6 posttransplant months of highest immunologic and infectious disease risk. Results were compared with those of 28 historical lung recipients treated with daclizumab induction and triple immunosuppression (tacrolimus-prednisone-azathioprine). RESULTS: Recipient pretreatment with both antilymphoid preparations allowed the use of postoperative tacrolimus monotherapy with prevention or control of acute rejection. Freedom from rejection was significantly greater with Campath than with Thymoglobulin (P = .03) or daclizumab (P = .05). After lymphoid depletion with Thymoglobulin or Campath, patient and graft survival at 6 months was 90% or greater. Patient and graft survival after 9 to 24 months is 84.2% in the Thymoglobulin cohort, and after 10 to 12 months, it is 90% in the Campath cohort. There has been a subjective improvement in quality of life relative to our historical experience. CONCLUSION: Our results suggest that improvements in lung transplantation can be accomplished by altering the timing, dosage, and approach to immunosuppression in ways that might allow natural mechanisms of alloengraftment and diminish the magnitude of required maintenance immunosuppression.
Authors: X Préville; M Flacher; B LeMauff; S Beauchard; P Davelu; J Tiollier; J P Revillard Journal: Transplantation Date: 2001-02-15 Impact factor: 4.939
Authors: Alyssa M Krasinskas; Daniel Kreisel; Michael A Acker; Joseph E Bavaria; Alberto Pochettino; Robert M Kotloff; Selim Arcasoy; Nancy Blumenthal; Malek Kamoun; Jonni S Moore; Bruce R Rosengard Journal: Transplantation Date: 2002-04-27 Impact factor: 4.939
Authors: Thomas E Starzl; Noriko Murase; Kareem Abu-Elmagd; Edward A Gray; Ron Shapiro; Bijan Eghtesad; Robert J Corry; Mark L Jordan; Paulo Fontes; Tim Gayowski; Geoffrey Bond; Velma P Scantlebury; Santosh Potdar; Parmjeet Randhawa; Tong Wu; Adriana Zeevi; Michael A Nalesnik; Jennifer Woodward; Amadeo Marcos; Massimo Trucco; Anthony J Demetris; John J Fung Journal: Lancet Date: 2003-05-03 Impact factor: 79.321
Authors: M V Brock; M C Borja; L Ferber; J B Orens; R A Anzcek; J Krishnan; S C Yang; J V Conte Journal: J Heart Lung Transplant Date: 2001-12 Impact factor: 10.247
Authors: Stuart J Knechtle; John D Pirsch; John H Fechner; Bryan N Becker; Andreas Friedl; Robert B Colvin; Lauralynn K Lebeck; L Thomas Chin; Yolanda T Becker; Jon S Odorico; Anthony M D'Alessandro; Munci Kalayoglu; Majed M Hamawy; Huaizhong Hu; Debra D Bloom; Hans W Sollinger Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Jay K Bhama; Aditya Bansal; Norihisa Shigemura; Christian A Bermudez; Yoshiya Toyoda Journal: Interact Cardiovasc Thorac Surg Date: 2013-07-11
Authors: Ngoc L Thai; Akhtar Khan; Kusum Tom; Deanna Blisard; Amit Basu; Henkie P Tan; Amadeo Marcos; John J Fung; Thomas E Starzl; Ron Shapiro Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: Ron Shapiro; Amit Basu; Henkie Tan; Edward Gray; Akhtar Kahn; Parmjeet Randhawa; Noriko Murase; Adriana Zeevi; Alin Girnita; Diana Metes; Roberta Ness; Debra C Bass; Anthony J Demetris; John J Fung; Amadeo Marcos; Thomas E Starzl Journal: J Am Coll Surg Date: 2005-04 Impact factor: 6.113
Authors: Susan Shyu; Mary Amanda Dew; Joseph M Pilewski; Annette J DeVito Dabbs; Diana B Zaldonis; Sean M Studer; Maria M Crespo; Yoshiya Toyoda; Christian A Bermudez; Kenneth R McCurry Journal: J Heart Lung Transplant Date: 2011-03-21 Impact factor: 10.247
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119